Docket Number:12A-1011005
Inventor:Yuan-Tsong Chen, Andrew Tai-Ann Cheng, Chien-Hsiun Chen, Chao-Shoun Lee, Ming-Ta Lee
IP Status:TW I510632, US9797015B2, ZL201480018706.9
Abstract:
Lithium has been a first-line choice for maintenance treatment in bipolar disorder to prevent relapse of mania and depression. A significant portion of the patients, however, does not respond to lithium treatment. We conducted a genome-wide association study among bipolar patients and identified a gene that differentiated between good and poor responders to lithium prophylaxis monotherapy. This gene also successfully differentiated between the good and poor responders in an independent follow-up cohort.
Fields of Application:
The gene has a strong potential to be used as clinical testing for predicting lithium treatment and can aid physicians for determining their patients’ response. This will allow non-responder to be identified early and allow them to other alternative medication.
Advantages when compared to the existing technologies:
Up to date, there is no clinical testing for predicting lithium treatment.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
